CHAMPIONS ONCOLOGY, INC. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CHAMPIONS ONCOLOGY, INC. stock issued during period, value, issued for services for the quarter ending 2018-04-30 was $22.00K.
- CHAMPIONS ONCOLOGY, INC. stock issued during period, value, issued for services for fiscal 2019 was $6.00K, a 83.78% decline from fiscal 2018.
- CHAMPIONS ONCOLOGY, INC. stock issued during period, value, issued for services for fiscal 2018 was $37.00K, a 15.91% decline from fiscal 2017.
- CHAMPIONS ONCOLOGY, INC. stock issued during period, value, issued for services for fiscal 2017 was $44.00K, a 0.00% change from fiscal 2016.
- CHAMPIONS ONCOLOGY, INC. stock issued during period, value, issued for services for fiscal 2016 was $44.00K.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2019-04-30 | $6.00K 10-K · filed 2020-07-28 | |
| 2018-04-30 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-07-29 | $37.00K 10-K · filed 2019-07-29 |
| 2017-04-30 | $44.00K 10-K · filed 2018-07-30 | |
| 2016-04-30 | $44.00K 10-K · filed 2017-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |